Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $36.7700 (-1.74%) ($36.7700 - $36.7700) on Wed. Jun. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.13% (three month average) | RSI | 65 | Latest Price | $36.7700(-1.74%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.2% a day on average for past five trading days. | Weekly Trend | TGTX advances 4.7% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) ARKK(59%) IBB(59%) IWO(59%) | Factors Impacting TGTX price | TGTX will decline at least -1.565% in a week (0% probabilities). VIXM(-45%) VXX(-38%) UUP(-19%) UNG(-3%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.565% (StdDev 3.13%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $37.64(-2.31%) | 10 Day Moving Average | $36.99(-0.59%) | 20 Day Moving Average | $35.44(3.75%) | To recent high | -26.7% | To recent low | 13.4% | Market Cap | $4.657b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |